drugset / Trial / NCT07033858
Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
RandomizedParallel-groupSingle-blindTreatment
Summary
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Timeline
- Start
- 2025-03-01
- Primary completion
- 2026-03-01
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 1 mg | — |
Indications
No indication recorded.